Lexent Bio is a precision oncology company. The company works to shrink cancer's role in our lives, first by helping patients and clinicians make better treatment decisions, faster. The Lexent Bio team hails from clinical, scientific, engineering, computer science, and business backgrounds, and share a passion for changing the way we understand and treat cancer. The company is taking on some of the hardest problems at the intersection of unexplored cancer biology, data science, and clinical medicine. The Confera™ Dx Assay system is the company's first product to move into commercialization.